Molecular Cancer | Naval Medical University Yang Bo and others develop new methods to better diagnose prostate cancer

Editor’s note iNature is China’s largest academic official account.
It is jointly created by the doctoral team of Tsinghua University, Harvard University, Chinese Academy of Sciences and other units.
The iNature Talent Official Account is now launched, focusing on talent recruitment, academic progress, scientific research information, interested parties can Long press or scan the QR code below to follow us.

iNature prostate cancer (PCa) is the most important malignant tumor in men.
In 2018, there were 1,276,106 new cases and 358,989 deaths worldwide.

The early diagnosis of PCa depends on the detection of prostate specific antigen (PSA).

However, due to its low specificity, the widespread use of PSA has led to many unnecessary biopsy complications.

Little is known about the profile and characteristics of circulating exosomal messenger RNA (emRNA), which hinders the accurate detection of circulating emRNA.

On March 30, 2021, Naval Medical University Wang Fubo and Yang Bo jointly published a research paper entitled "Circulating exosomal mRNA profiling identifies novel signatures for the detection of prostate cancer" in Molecular Cancer (IF=15.
30).
The research passed Comparing the RNA sequencing data of circulating exosomes with the corresponding data in tissues illustrates the different characteristics of emRNA compared with tissue mRNA.

Then, the research developed an improved emRNA detection strategy based on the characteristics of circulating emRNA.

Using an optimized detection strategy, we further verified the prostate cancer (PCa)-related emRNA found by emRNA-seq in a large number of patients, and used logistic regression analysis to determine the emRNA markers for PCa screening and diagnosis.

The screening feature based on circulating emRNA can generate a 0.
948 area under the ROC curve (AUC), thereby distinguishing PCa patients from healthy controls.

Diagnostic markers based on circulating emRNA also show excellent performance in predicting prostate biopsy results (AUC: 0.
851).

In summary, the research developed an optimized emRNA detection strategy and identified novel emRNA biomarkers for the detection of PCa.

Prostate cancer (PCa) is the most important malignant tumor in men.
In 2018, there were 1,276,106 new cases and 358,989 deaths worldwide.

The accurate early detection of PCa is one of the key issues in PCa management.

The early diagnosis of PCa depends on the detection of prostate specific antigen (PSA).

However, due to its low specificity, the widespread use of PSA has led to many unnecessary biopsy complications.

In addition, previous studies have shown that many PCa cases, including high-grade PCa (HGPCa) cases, have been missed because they can display PSA levels within the normal range.

Therefore, there is an urgent need to identify new biomarkers with higher accuracy for the early detection of PCa.

In recent years, exosomal RNA (exRNA) has played an increasing role in cancer detection.

Extracellular long RNA (exLR), mainly messenger RNA (mRNA), may be a potential biomarker for glioma, hepatocellular carcinoma (HCC), pancreatic ductal adenocarcinoma (PDAC), etc.

The characteristics of circulating exosomal mRNA (emRNA) are poorly understood, which hinders accurate detection of emRNA.

Early detection of PCa and HGPCa, but no research has focused on the diagnostic potential of circulating emRNA.

The study compared the RNA sequencing data of circulating exosomes with the corresponding data in tissues, illustrating the different characteristics of emRNA compared with tissue mRNA.

Then, the research developed an improved emRNA detection strategy based on the characteristics of circulating emRNA.

Using an optimized detection strategy, we further verified the prostate cancer (PCa)-related emRNA found by emRNA-seq in a large number of patients, and used logistic regression analysis to determine the emRNA markers for PCa screening and diagnosis.

The screening feature based on circulating emRNA can generate a 0.
948 area under the ROC curve (AUC), thereby distinguishing PCa patients from healthy controls.

Diagnostic markers based on circulating emRNA also show excellent performance in predicting prostate biopsy results (AUC: 0.
851).

In summary, the research developed an optimized emRNA detection strategy and identified novel emRNA biomarkers for the detection of PCa.

Reference message: https://molecular-cancer.
biomedcentral.
com/articles/10.
1186/s12943-021-01349-z